Enzalutamide

What is Enzalutamide?

Enzalutamide is a potent, orally administered androgen receptor inhibitor primarily used in the treatment of prostate cancer. Classified under the ATC code L02 (Antineoplastic and immunomodulating agents, Endocrine therapy), it represents a significant advancement in managing hormone-sensitive and castration-resistant forms of the disease. This medication works by targeting the androgen receptor signaling pathway, which is crucial for the growth and survival of prostate cancer cells.

As a non-steroidal antiandrogen, Enzalutamide offers a distinct mechanism of action compared to older therapies, providing a more comprehensive blockade of androgen receptor activity. It is prescribed for men whose prostate cancer has progressed despite conventional hormone therapy, offering a vital treatment option to extend life and improve quality of life for patients facing advanced stages of the disease.

Mechanism of Action

Enzalutamide exerts its anti-tumor effects by acting as a highly specific androgen receptor signaling inhibitor. Unlike traditional antiandrogens, it targets multiple steps in the androgen receptor signaling pathway, effectively disrupting the growth and survival of prostate cancer cells. Its key mechanisms include:

• Inhibition of Androgen Binding: Enzalutamide directly competes with androgens (like testosterone and dihydrotestosterone) for binding to the androgen receptor, preventing its activation.
• Impairment of Androgen Receptor Nuclear Translocation: It prevents the activated androgen receptor from moving into the cell nucleus, where it would normally bind to DNA and initiate gene transcription.
• Blockade of DNA Binding and Transcriptional Activity: Even if the androgen receptor somehow reaches the nucleus, Enzalutamide inhibits its ability to bind to DNA and activate the transcription of genes responsible for prostate cancer cell growth and proliferation.

Medical Uses

Enzalutamide is a cornerstone therapy in the management of various stages of prostate cancer. Its primary medical uses include:

• Metastatic Castration-Resistant Prostate Cancer (mCRPC): For patients whose cancer has spread to other parts of the body and continues to progress despite medical or surgical castration.
• Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC): For patients whose cancer has not spread but continues to progress despite castration, and who are at high risk for developing metastatic disease.
• Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Used in combination with androgen deprivation therapy (ADT) for patients whose cancer has spread and is still responsive to hormone therapy.

While primarily indicated for prostate cancer, Enzalutamide is not approved for other types of cancer or conditions. Its efficacy and safety have been rigorously established in the context of advanced prostate cancer treatment.

Dosage

The recommended dosage of Enzalutamide is generally consistent across its approved indications. It is administered orally, typically once daily.

It is crucial to follow the prescribing physician's instructions carefully regarding dosage and administration. Enzalutamide can be taken with or without food.

Side Effects

Like all medications, Enzalutamide can cause side effects, although not everyone experiences them. Patients should discuss any concerns with their healthcare provider.

Common Side Effects:

• Fatigue and asthenia (weakness)
• Hot flashes
• Hypertension (high blood pressure)
• Diarrhea
• Musculoskeletal pain
• Headache
• Peripheral edema (swelling in limbs)
• Nausea
• Dizziness

Rare but Serious Side Effects:

• Seizures: A significant concern, particularly in patients with a history of seizures or predisposing factors.
• Posterior Reversible Encephalopathy Syndrome (PRES): A rare neurological disorder.
• Cardiovascular events: Including ischemic heart disease and cardiac failure.
• Neutropenia: A decrease in white blood cells, increasing infection risk.
• Interstitial Lung Disease: A rare but serious lung condition.
• Falls and fractures: Due to dizziness or other neurological effects.

Warnings

Before initiating treatment with Enzalutamide, patients should inform their doctor about all existing medical conditions and medications they are taking.

Contraindications:

• Pregnancy: Enzalutamide is contraindicated in women who are or may become pregnant, as it can cause fetal harm. Men being treated with Enzalutamide should use effective contraception if their partner is pregnant or of childbearing potential.
• Hypersensitivity: Individuals with a known hypersensitivity to Enzalutamide or any of its excipients should not use this medication.

Caution is advised in patients with a history of seizures, cardiovascular disease, or significant hepatic or renal impairment. Regular monitoring for blood pressure and potential seizure activity is recommended during treatment.

Disclaimer: This article provides general medical information and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment. Do not disregard professional medical advice or delay in seeking it because of something you have read in this article. The information provided here is for informational purposes only and should not be used for self-diagnosis or self-treatment. Consult a healthcare professional before making any decisions about your health or treatment.